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1772 | Nanoscale, 2013, 5, 1772–177Virus-mimicking nano-constructs as a contrast agent for
near infrared photoacoustic imaging†‡
Sharad Gupta,§a Muhammad R. Chatni,§b Ayala L. N. Rao,c Valentine I. Vullev,a
Lihong V. Wang*b and Bahman Anvari*aWe report the ﬁrst proof-of-principle demonstration of photo-
acoustic imaging using a contrast agent composed of a plant virus
protein shell, which encapsulates indocyanine green (ICG), the only
FDA-approved near infrared chromophore. These nano-constructs
can provide higher photoacoustic signals than blood in tissue
phantoms, and display superior photostability compared to non-
encapsulated ICG. Our preliminary results suggest that the constructs
do not elicit an acute immunogenic response in healthy mice.In this communication, we report the rst demonstration of
near infrared (NIR) photoacoustic imaging (PAI) using a new
nano-construct composed of biological and organic materials as
the contrast agent. Specically, the construct is comprised of a
protein shell, puried from the plant-infecting brome mosaic
virus (BMV), that encapsulates indocyanine green (ICG), the
only FDA-approved NIR chromophore. We refer to these virus-
resembling nano-constructs as optical viral ghosts (OVGs) since
the genomic content of the wildtype BMV is eliminated and
replaced with ICG, while the capsid protein (CP) subunits
remain as the encapsulating shell.
Recently, attention has been given to the use of biological
materials, particularly viruses, as a platform for the delivery of
imaging and therapeutic agents.1–5 Plant and recombinant
adenoviruses have been investigated as potential vaccine
carriers in gene therapy and oncolytic viral therapy.6–8 Viruses
have also been used to encapsulate inorganic materialsof California, Riverside, Riverside, CA
shington University in St. Louis, St. Louis,
stl.edu
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6including quantum dots (QDs),9 gold,10 and magnetic nano-
particles.11 Virus-based protein cages, assembled from the
cowpea chlorotic mottle virus,12 and the capsid of the MS2
bacteriophage coated with gadolinium have been investigated
as MRI contrast agents.12,13
In comparison to animal viruses, plant viruses are easier to
produce and purify, and are chemically and structurally more
stable.5,14,15 For example, surface conjugation of the cowpea
mosaic virus (CPMV) with a folic acid-PEG moiety has been
demonstrated in vitro to allow specic recognition of tumor
cells bearing the folate receptor.16 The potato virus X surface-
labeled with Oregon Green 488 and Alexa Fluor 647 has been
successfully used to image mouse broblasts and human
cervical cancer cells in vitro.17 Recently, the surface of RNA
containing CPMV was labeled with Alexa Fluor 555, a non-NIR
uorophore, and used for in vivo vascular imaging in mice and
chick embryos.18 Results of this study are extremely encour-
aging, in that they demonstrate the potential of using a uo-
rescently labeled plant virus for successful in vivo vascular
imaging. In another recent study, uorescence imaging of
human prostate tumor xenogras on the chicken chorioallan-
toic membrane animal model was achieved by using CPMV
decorated with NIR Alexa Flour 647, and functionalized with
peptide bombesin to target gastrin-releasing peptide recep-
tors.19 An engineered variant of CPMV has also been used as a
template for fabrication of silica nanoparticles.20
We recently provided the rst report of successful fabrication
of the genome-depleted BMV virions doped with ICG, and their
utility in uorescence imaging.21 ICG (molecular weight of its
sodium salt, MW(C43H47N2NaO6S2) z 775 Da) is an excellent
NIR light absorber with reported values of its molar extinction
coeﬃcient (3) in aqueous media ranging between 8  104 and
1.2  105 l mol1 cm1 at 780 nm, which corresponds to
absorption cross-section, sa (780 nm), of about 3  1016 to 4.6
 1016 cm2.22–24 Therefore, the strong absorption properties of
ICG can be explored as an alternative to radiative-based (e.g.,
uorescence) imaging modalities. Photoacoustic (PA) tech-
niques oﬀer such an absorption-mediated imaging approach.This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineIn PAI, light is absorbed, and converted into heat. Depending
on the radiant exposure levels, temperature rises on the order of
z1 C is suﬃcient to produce acoustic waves, which are then
detected by ultrasound detector(s).25,26 The PA approach keeps
the merits of optical imaging techniques, such as optical
sensitivity and radiation safety, while providing high ultra-
sound-dened spatial resolution in optical quasi-diﬀusive and
diﬀusive regimes. As an endogenous contrast agent for PAI,
hemoglobin has been investigated in several applications such
as visualizing brain structure and lesions,25,27 delineating tumor
vasculature,28 monitoring hemodynamics,29 imaging small
animals,30 andmeasuring blood ow inmicrovasculature.31One
of the key properties of tumor growth is neo-angiogenesis, and
the PA approach has been used to detect tumor growth by
imaging the hemoglobin in such vasculatures. Melanin, as
another endogenous PA contrast agent, has been used for the
diagnosis, prognosis, and treatment planning of melanotic
melanoma.32,33
We present a transmission electronmicroscope (TEM) image
of OVGs aer 15 days of storage in BMV suspension buﬀer
(Fig. 1A), conrming that the OVGs remained intact in the
suspension buﬀer over this time interval. From the recorded
TEM images, we assessed the size and themonodispersity of the
OVGs. The image analysis yielded a diameter of 29.7  3.1 nm,
where the error limit of the mean represents one standard
deviation. We have previously employed dynamic light scat-
tering (DLS) to estimate the size of ICG-doped viral construct,
similar to the OVGs used in this study, i.e., BMV CP to ICG
concentration ratio of 4, and ICG concentration of ~30 mM.21
Our DLS analysis yielded OVG diameter of 24.3  3.9 nm,21
which was in a good agreement with our TEM results.
We present an illustrative absorption spectrum of OVGs in
BMV suspension buﬀer (Fig. 1B). This set of OVGs was fabri-
cated using 20 mg ml1 of ICG (z26 mM), and the nal solution
containing the OVGs was diluted by a factor of 10. The ratio of
BMV CP to ICG concentration was xed at 4 in fabricating the
OVGs used in this study. The OVG absorption spectrum displays
maximum absorbance peaks atz700 and 800 nm. The peak at
270 nm corresponds to absorption by the CP subunits encap-
sulating ICG, consistent with our previous report.21 The spec-
trum of the OVG supernatant solution, measured aer OVGFig. 1 Physical characterization of OVGs. (A) TEM image of OVGs obtained after
15 days of storing the OVGs in BMV suspension buﬀer. (B) Absorption spectrum of
OVGs (black trace) corresponding to constructs fabricated using ICG concentra-
tion of 20 mg ml1 (z26 mM). The ﬁnal solution containing the OVGs was
subsequently diluted ten times prior to obtaining the spectrum. The red trace in
panel B corresponds to the spectrum of the supernatant solution.
This journal is ª The Royal Society of Chemistry 2013fabrication, did not display any absorbance over the entire
UV-NIR spectral band, conrming that almost all the ICG
introduced during the fabrication process was incorporated
into the constructs (i.e.,z100% loading eﬃciency), and that the
entire CP subunits were utilized in forming the OVGs.
We present the averaged B-scan of tubes containing various
samples embedded at and below the surface of chicken breast
tissue as a phantom (Fig. 2). The designation of samples is as
follows: sample 10S represents OVGs prepared using 10 mg ml1
of ICG (z13 mM) during fabrication; 20S is the OVG sample
constructed using 20 mg ml1 of ICG (z26 mM); 40S is the OVG
sample constructed using 40 mg ml1 of ICG (z52 mM); 20S/4 is
the 20S sample diluted by factor of four; and 40S/4 and 40S/10
are the 40S samples diluted by factors of 4 and 10, respectively.
The near and far walls of all the tubes are visible. The mean
amplitude of the PA signal at the top surface of the tubes was
determined and plotted as a function of excitation wavelength.
Regardless of the placement positions of the tubes within the
chicken breast phantom, the tubes containing the 40S OVG
solution gave the highest PA signal since they had the highest
concentration of ICG loaded into the OVG constructs. The
amplitude of the PA signal emitted from the tube containing the
40S OVG solution was about 3–4 times higher than that of blood
independent of the tubes depth in the phantom. The 20S OVG
solution had two-fold higher PA signal than blood with tubes
placed at the surface (Fig. 2A) or 6 mm subsurface (Fig. 2B).
The PA signals from diluted 20S/4 and 40S/10 OVG solutions
were similar in magnitude, but lower than that of blood in
response to excitation wavelengths longer than 770 nm
regardless of the placement depth of the tubes. Independent ofFig. 2 Averaged B-scan photoacoustic images in response to 790 nm excitation
(left panel) and the corresponding PA signal amplitudes as a function of excitation
wavelength (right panel). Photoacoustic images correspond to tubes containing
the OVG samples and oxygenated blood in ex vivo chicken tissue phantoms: (A)
no overlaid chicken tissue, (B) z6 mm overlaid chicken tissue, and (C) z14 mm
overlaid chicken tissue. Left to right in B-scan images: Oxygenated blood, 10S,
20S/4, 20S, 40S/10, 40S/4, and 40S OVG solutions. The designation of samples is
as follows: sample 10S represents OVGs prepared using 10 mg ml1 (z13 mM) of
ICG during fabrication; 20S is the OVG sample constructed using 20 mg ml1 of
ICG; 40S is the OVG sample constructed using 40 mg ml1 of ICG; 20S/4 is the 20S
sample diluted by factor of four; and 40S/4 and 40S/10 are the 40S samples
diluted by factors of 4 and 10, respectively.
Nanoscale, 2013, 5, 1772–1776 | 1773
Fig. 4 Cytokine levels in healthy mice injected with puriﬁed BMV CP, or LPS
(positive control). Each bar represents the mean standard deviation values from
three wells (some of the errors bars were too small to be shown).
Nanoscale Communication
Pu
bl
ish
ed
 o
n 
08
 Ja
nu
ar
y 
20
13
. D
ow
nl
oa
de
d 
by
 C
al
ifo
rn
ia
 In
sti
tu
te
 o
f T
ec
hn
ol
og
y 
on
 2
2/
06
/2
01
6 
22
:4
0:
42
. 
View Article Onlinethe tubes depth in the phantom, the PA signal from blood
increased approximately by 50% when changing the excitation
wavelength from 760 nm to 820 nm, which is consistent with
absorption of oxygenated blood in that wavelength range.
When tubes were placed 6 mm below the surface of the
phantom, there was a reduction in the PA signal from the 10S
and 40S/4 OVG samples (Fig. 2C). This reduction could be due
to the non-uniformity in the optical properties across the whole
tissue, resulting in higher attenuation of the laser light at some
part of the tissue.
To investigate the feasibility of deeper imaging, z14 mm
thick chicken breast tissue was overlaid on top of the seven
tubes. The PA signal from the 40S OVG solution remained the
highest, and approximately three times higher than that of
blood (Fig. 2C). The PA signal from the 20S OVG solution was
similar to that of blood across the entire wavelength range.
The PA signals for both OVG (20S) and free ICG (20 mg ml1)
in BMV suspension buﬀer solutions decreased with increasing
number of laser pulses (Fig. 3). However, the PA signal associ-
ated with free ICG solution was lower than that associated with
the OVG solution for all laser number pulses investigated, and
this diﬀerence increased with increasing number of the laser
pulse. For example, the PA signal from the OVG solution was
reduced by z20% from its maximum intensity, whereas the
signal from the ICG solution decreased byz45%, both aer 50
laser pulses.
While the safety of OVGs needs to be established based on
future in vivo studies, our previous in vitro results indicate that
mammalian cells remain viable following internalization of
these constructs.21 To our knowledge, there is no prior appli-
cation of plant viruses, or constructs derived from plant viruses
in humans. Herein, we report the rst results to assess the
immunogenic eﬀects of the BMV CP in mice (Fig. 4). We
administered puried BMV CP subunits (100 mg) into healthy
mice through tail vein injection. As positive control, we
administered z80 mg of lipopolysaccharide (LPS) (80 ml injec-
tion volume), a known immunogenic agent.34 Following
euthanasia at one or six hours post-injection, we screened for
the production of interleukin-6 (IL-6), tumor necrosis factor-aFig. 3 Photoacoustic amplitude response of OVGs (upper trace) and non-
encapsulated ICG (lower trace) as a function of applied laser pulses.
1774 | Nanoscale, 2013, 5, 1772–1776(TNFa), and interferon-g (IFNg) cytokines. IL-6 and TNFa are
among inammation-associated cytokines, secreted by macro-
phages and other cell types. They stimulate the production of
specic plasma proteins during the acute phase following an
inammatory stimulus.35 IFNg is a cytokine critical for innate
and adaptive immunity against viral and intracellular patho-
gens, and tumor control.36
In response to injection of the BMV CP subunits, very low
levels of the cytokines IL-6, TNFa, and IFNg (<6 pg ml1) were
measured. However, administration of LPS resulted in
production of approximately 1,100 pg ml1 of TNFa, 5000 pg
ml1 of IFNg, and 10 000 pg ml1of IL-6 at six hours post-
injection. Although further dose–response and multiple injec-
tion studies must be performed, these preliminary results
suggest that OVGs may not elicit an inammatory response.
In a recent study, the toxicity of the CPMVwas investigated in
mice.37 Histological examinations of various organs revealed no
pathological changes. Specic detection of apoptotic cells in
liver, spleen, lung, kidneys, and heart was not observed. In
another study, the biodistribution of cowpea protein cages was
investigated in mice.38 There wasz65% elimination of protein
cages through the urine and feces at 24 hours post tail vein
injection of na¨ıve and immunized mice. The investigators
reported no overt toxicity aer a single injection, and indicated
that protein cages may serve as safe, biocompatible, nano-
platforms for applications in medicine.
While ICG has been used clinically as a uorescence imaging
probe in retinal angiography as well as cardiovascular and liver
function assessment,39–41 its main drawbacks are its rapid
clearance from the vasculature with nearly exclusive uptake by
hepatocytes, and immense propensity for aggregation resulting
in uorescence quenching. Specically, aer intravascular
administration, ICG readily binds to albumin and high-density
lipoproteins such as alpha-1 lipoprotein,42 and is eliminated
from circulation with plasma clearance half-life on the order of
3–4 minutes.43,44 Encapsulation of ICG can provide a method
to shield the ICG from non-specic interactions with
plasma proteins, and increase its lifetime within plasma. Sax-
ena et al. have reported that ICG encapsulation into polyThis journal is ª The Royal Society of Chemistry 2013
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View Article Online(DL-lactic-co-glycolic acid) (PLGA) constructs resulted in nearly
six times higher ICG levels within the plasma at one hour post
tail vein injection in mice, as compared to non-encapsulated
ICG.45 At four hours post-injection, there was still detectable ICG
within the plasma when administered in nano-encapsulated
formulation.45 Our group has previously reported that encap-
sulation of ICG into polymeric nano-constructs, composed of
poly(allylamine) hydrochloride cross-linked with disodium
biphosphate, enhances the contrast of in vivo uorescent
images from heart and lungs for at least up to 90 minutes aer
tail vein injection in mice,46 indicating the prolonged circula-
tion of ICG when encapsulated. While future studies are
required, encapsulation of ICG into virus-based constructs,
such as the OVGs, may provide a method for prolonged PAI as
compared to PAI in conjunction with non-encapsulated ICG.
Our results demonstrate that encapsulation in the OVG
constructs improves the photostability of ICG (Fig. 3). The
observed loss of the NIR absorption of free ICG upon irradiation
can be ascribed to photo-induced breaking of the p-conjugation
along the oligo-methine linker between the two aromatic
moieties in the dye molecule. Therefore, photo-addition to the
altering double bonds (producing a leuco form of the dye with
converted sp2 to sp3 carbon hybridization) and/or photo-
cleavage of the oligo-methine linker can account for the
observed decrease in the NIR absorption and emission of free
ICG.47,48 Holzer et al. showed that placing ICG in an aprotic
organic solvent leads to more than about two orders of
magnitude decrease in the time-zero degradation yield (fD,0) of
the dye in comparison with fD,0 for aqueous solutions.48 Similar
eﬀect was observed when ICG was dissolved in human plasma
where the dye can bind to the abundant human serum albumin
and other proteins.48 Although the exact chemical mechanism
of ICG photo-degradation is not known, these reported evidence
indicate that the removal of nucleophiles, such as water mole-
cules, from the microenvironment of the cyanine dye, consid-
erably improves its photostability. Our ndings are consistent
with this previous evidence. Encapsulation of ICG within the
constructs limits the access of water to the dye molecules,
resulting in the observed improvement in the ICG
photostability.
OVGs may provide a versatile platform for development of a
multi-functional nano-construct with potential for site-specic,
and combined deep tissue optical imaging and phototherapy.
The abundance of naturally present amines on the CP shell
provides addressable sites for covalent attachment of a variety
of targeting moieties on the surface of OVGs so that the
constructs can be used to identify molecular biomarkers of a
disease. As an example, in a recent study, we functionalized the
surface of OVGs with the anti-epidermal growth factor receptor,
and subsequently utilized these constructs for targeted uo-
rescence imaging of human bronchial epithelial cancer cells in
vitro.49 Such functionalized OVGs may potentially be used in
conjunction with PAI for targeted imaging at high optical
contrast. Fabrication and functionalization procedures are
relatively inexpensive, and easily achieved at room temperature
and pressure without the need for any chemical synthesis
procedures.This journal is ª The Royal Society of Chemistry 2013Conclusions
We report the rst proof-of-principle demonstration of NIR-PAI
using virus-mimicking particles. When used at appropriate
amounts, OVGs displayed amuch stronger photoacoustic signal
than that emitted by blood over the wavelength range of 760–
820 nm. OVGs also demonstrated superior photostability in
comparison to non-encapsulated ICG in solution. Our prelimi-
nary results showed that OVGs did not elicit an acute immu-
nogenic response in healthy mice.Acknowledgements
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